Esperion to Report First Quarter 2024 Financial Results on May 7
Esperion to Report First Quarter 2024 Financial Results on May 7
ANN ARBOR, Mich., April 23, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report first quarter 2024 financial results before the market opens on Tuesday, May 7, 2024.
Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. Please click here to pre-register to participate in the conference call and obtain your dial in number and PIN.
A live audio webcast can be accessed on the investor and media section of the Esperion website at esperion.com/investor-relations/events. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days.
Esperion Therapeutics
At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases. The status quo is not meeting the health needs of millions of people with high cholesterol – that is why our team of passionate industry leaders is breaking through the barriers that prevent patients from reaching their goals. Providers are moving toward reducing LDL-cholesterol levels as low as possible, as soon as possible; we provide the next steps to help get patients there. Because when it comes to high cholesterol, getting to goal is not optional. It is our life’s work. For more information, visit esperion.com and esperionscience.com and follow us on Twitter at twitter.com/EsperionInc.
Esperion Contact Information:
Investors:
Alexis Callahan
investorrelations@esperion.com
(406) 539-1762
Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438
密歇根州安娜堡,2024 年 4 月 23 日(環球通訊社)——Esperion(納斯達克股票代碼:ESPR)今天宣佈,將在 2024 年 5 月 7 日星期二開盤前公佈 2024 年第一季度財務業績。
發佈後,管理層將在東部時間上午 8:00 舉辦網絡廣播,討論這些財務業績並提供業務更新。請點擊此處預先註冊參加電話會議並獲取您的撥入號碼和 PIN 碼。
您可以在 Esperion 網站的投資者和媒體部分觀看現場音頻網絡廣播:esperion.com/investor-relations/events。通話結束後大約兩小時即可訪問網絡廣播重播,並將在公司網站上存檔大約 90 天。
Esperion Therapeutics
在 Esperion,我們發現、開發和商業化創新藥物,以幫助改善患有心血管和心臟代謝疾病或有風險的患者的治療結果。現狀無法滿足數百萬高膽固醇患者的健康需求——這就是爲什麼我們充滿激情的行業領導者團隊正在突破阻礙患者實現目標的障礙。醫療服務提供者正在努力盡快降低低密度脂蛋白膽固醇水平;我們提供了幫助患者到達那裏的後續步驟。因爲當談到高膽固醇時,達到目標不是可選的。這是我們一生的工作。欲了解更多信息,請訪問esperion.com和esperionscience.com,並在 Twitter 上關注我們:twitter.com/EsperionInc。
Esperion 聯繫信息:
投資者:
Alexis Callahan
Investorrelations@esperion.com
(406) 539-1762
媒體:
Tiffany Aldrich
Corporateteam@esperion.com
(616) 443-8438
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧